clofilium has been researched along with ly 97241 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gessner, G; Heinemann, SH | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Sen, S; Sinha, N | 1 |
| Arena, JP; Kass, RS | 1 |
| Busch, AE; Heinemann, SH; Lang, F; Schönherr, R; Suessbrich, H | 1 |
| Steidl, JV; Yool, AJ | 1 |
| Finlayson, K; January, CT; Kelly, JS; Sharkey, J; Turnbull, L | 1 |
7 other study(ies) available for clofilium and ly 97241
| Article | Year |
|---|---|
Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241.
Topics: Animals; Cell Line; Cricetinae; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Humans; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quaternary Ammonium Compounds; Xenopus | 2003 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Block of heart potassium channels by clofilium and its tertiary analogs: relationship between drug structure and type of channel blocked.
Topics: Animals; Anti-Arrhythmia Agents; Female; Guinea Pigs; Heart; Ion Channels; Male; Potassium; Quaternary Ammonium Compounds; Structure-Activity Relationship; Time Factors | 1988 |
Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241.
Topics: Animals; Anti-Arrhythmia Agents; Cation Transport Proteins; Cloning, Molecular; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Humans; Kinetics; Membrane Potentials; Mutagenesis, Site-Directed; Oocytes; Point Mutation; Potassium Channels; Potassium Channels, Voltage-Gated; Quaternary Ammonium Compounds; Recombinant Proteins; Shal Potassium Channels; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG; Xenopus laevis | 1997 |
Distinct mechanisms of block of Kv1.5 channels by tertiary and quaternary amine clofilium compounds.
Topics: Animals; Female; Hydrogen-Ion Concentration; Kv1.5 Potassium Channel; Membrane Potentials; Oocytes; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quaternary Ammonium Compounds; Rats; Recovery of Function; Time Factors; Xenopus laevis | 2001 |
[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.
Topics: Anti-Arrhythmia Agents; Benzimidazoles; Binding, Competitive; Cation Transport Proteins; Cell Line; Cell Membrane; DNA-Binding Proteins; Drug Evaluation, Preclinical; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Haloperidol; Humans; Patch-Clamp Techniques; Phenethylamines; Pimozide; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quaternary Ammonium Compounds; Sulfanilamides; Sulfonamides; Terfenadine; Trans-Activators; Transcriptional Regulator ERG; Transfection; Tritium | 2001 |